Skip to content
Screener

Aquestive Therapeutics, Inc. AQST Other — Total General and Administrative Expenses

Other product segments

Personnel costs
$4.8M-27.1%

Similar metrics at other companies

CorMedix logo
CRMDOther general and administrative — Total general and administrative expense
$11.19M+293%
TMH
TMHCCentral — General and administrative expenses
$8.51M+5.3%
Rein Therapeutics Inc. logo
RNTXFacilities And Other Expenses — General And Administrative Expense
$508K+8.1%
Beam Therapeutics logo
BEAMExternal General And Administrative Expenses — General And Administrative Expense
$13.37M+149%
Solid Biosciences Inc. logo
SLDBExternal General And Administrative Expense — General And Administrative Expense
$6.33M+19.9%
Solid Biosciences Inc. logo
SLDBInternal General And Administrative Expense — General And Administrative Expense
$4.73M+40.9%

Other financials

Income statement

See full
Revenue$13.8M+38.1%
Gross profit$9.8M+80.1%
Operating income-$8.2M+27.7%
Net income-$22.9M-68.8%
EPS (diluted)-$0.18-28.6%

Balance sheet

See full
Cash & equivalents$98.5M+62.7%
Total debt$63.4M+6.0%
Total equity-$56.6M+22.0%
Total assets$132.1M+41.0%

Cash flow

See full
Operating cash flow-$9.4M-19.3%
CapEx$212.0K+98.1%
Free cash flow-$9.7M-20.3%

Valuation

See full
Market cap$538.25M+40.4%
Enterprise value$503.14M+31.5%
P/S10×+1.3×

Profitability

See full
Gross margin67%+5.9pp
Operating margin-97.5%-15.0pp
Net margin-144.6%-2.6pp
FCF margin-85%-17.0pp

Returns & leverage

See full
Return on equity121.1%
Debt / equity-1.1×
Current ratio7.2×+3.7×

Where this comes from

Reported directly by Aquestive Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 4:10 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001398733-26-000042
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total Selling expenses2,1743,5204,0956,476
General & Administrative expenses:
Personnel costs56,6025,17612,11110,016
Other65,2874,0098,83415,285
Total General and Administrative Expenses11,8899,18520,94525,301
Total Selling, General and Administrative Expenses14,06312,70525,04031,777
Total costs and expenses22,04221,37140,69249,456
Loss from operations(8,223)(11,368)(12,427)(30,733)

Item 1. FINANCIAL STATEMENTS (Unaudited)

FAQ

What is Aquestive Therapeutics, Inc.'s other — total general and administrative expenses?
Aquestive Therapeutics, Inc. (AQST) reported other — total general and administrative expenses of $5.29M in Q2 2026.
How has Aquestive Therapeutics, Inc.'s other — total general and administrative expenses changed year-over-year?
Aquestive Therapeutics, Inc.'s other — total general and administrative expenses increased by 31.9% year-over-year, from $4.01M to $5.29M.
What is the long-term trend for Aquestive Therapeutics, Inc.'s other — total general and administrative expenses?
Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s other — total general and administrative expenses has grown at a 46.5% compound annual growth rate (CAGR), from $19.34M to $41.53M.
What does other — total general and administrative expenses mean?
This metric captures the overhead and operational support costs required to manage the segment's day-to-day business activities, excluding direct production or sales costs. It includes allocations for executive management, legal, human resources, and other corporate functions supporting the segment's operations. Tracking this metric is essential for evaluating the segment's operational leverage and the efficiency of its administrative infrastructure.

Ask your AI about Aquestive Therapeutics, Inc.'s other — total general and administrative expenses.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude